|
|
News Breaks
|
November 10, 2009
|
| 07:34 EDT |  | MYGN |
| theflyonthewall.com: | Myriad Genetics weakness likely related to legal concerns, says UBS | | UBS said Myriad Genetics share weakness is likely related to yesterday's Supreme Court hearings for the Bilski case, which raises issues regarding non-tangible inventions, which include certain diagnostic tests, and whether they should be patentable like physical devices. The analyst does not have any comments on the merit of the case and maintains their Buy rating. :theflyonthewall.com |
|
|
News For MYGN From The Last 14 Days Check below for free stories on MYGN the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 2, 2012
|
| 16:19 EDT |  | MYGN |
| theflyonthewall.com: | Myriad Genetics announces positive results for Prolaris | | Myriad Genetics announced that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented at the 2012 Genitourinary Cancers Symposium. The study concluded that the Prolaris score, which analyzes the expression level of 46 cell cycle progression genes, demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence. :theflyonthewall.com |
|
|
February 1, 2012
|
| 09:43 EDT |  | MYGN |
|
|
January 31, 2012
|
| 16:16 EDT |  | MYGN |
| theflyonthewall.com: | Myriad Genetics raises FY12 EPS view to $1.24-$1.28 from $1.20-$1.25 | | EPS consensus is $1.24. The company also raises its FY12 revenue view to $465M-$475M from $445M-$465M vs. consensus $461.45M. :theflyonthewall.com |
| | 16:15 EDT | | MYGN |
|
|
|
|
|
Subscribe for More Information